University of Miami
The purpose of this research study is to see the effects (good or bad) of Lorigerlimab on patients with pancreatic adenocarcinoma (PDAC) and homologous recombination deficiency (HRD).
Inclusion Criteria: * 1\. Voluntarily agree to participate by giving signed, dated, and written informed consent prior to any study-specific procedures. * 2\. ≥ 18 years of age. * 3\. Histologically confirmed pancreas carcinoma with metastatic disease. Neuroendocrine neoplasms are not eligible. Adenosquamous, squamous and acinar histologies are allowed provided criteria #5 is fulfilled, and these histologies comprise no more than 10% of the total accrual. * 4\. Measurable disease on baseline imaging by CT (or MRI where CT is contraindicated) based on RECIST 1.1. * 5\. Documented germline muta…
Participants will be administered 6mg/kg of Lorigerlimab intravenously (IV) on day 1 of every three (3) week cycle (Q3W).
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.